However, results from the EVIDENCE trial showed that adjuvant icotinib significantly improves DFS in patients with EGFR-mutant stage II-IIIA NSCLC after complete tumor resection compared with adjuvant chemotherapy (47.0 vs. 22.1 months) (12). This evidence concerns the gene EGFR and non-small cell lung carcinoma.